AKAO


Needham Shares Two Cents on Achaogen (AKAO) Following Mixed FDA Verdict

It’s a short and dramatic plunge for Achaogen (NASDAQ:AKAO). Today, the drug maker’s shares lost nearly 24% following the news that the FDA …

Cowen Spotlights Opportunity in Achaogen (AKAO) Despite BSI Setback

Cowen’s Chris Shibutani pinpoints enticing commercial prospects ahead for AKAO’s plazomicin.

Needham Remains Bullish on Achaogen (AKAO) Stock Despite FDA AdCom Setback

It’s a short and dramatic plunge for Achaogen (NASDAQ:AKAO). Today, the drug maker’s shares lost 25% of their value following the news that …

Achaogen (AKAO) Shares Plummet 26% Following Disappointing AdCom Vote on BSI; Cowen Shares Insights

Cowen’s Chris Shibutani remains confident on AKAO as he angles for plazomicin’s timely approval in cUTI by the end of June.

Achaogen (AKAO): Will cUTI Asset Impress Today’s AdCom? Cowen Shares Two Cents

Cowen’s Chris Shibutani likes AKAO’s risk-reward set up ahead of today’s AdCom Meeting review of plazomicin.

Watch Out for These Pharmaceutical Players Racing Toward FDA Approvals

Will the FDA writing on the wall bode well for three pharmaceutical firms raring for a PDUFA nod this summer? Achaogen (NASDAQ:AKAO) complicated …

William Blair Boosts Price Target for Achaogen Inc (AKAO) as EPIC and CARE Top-Line Data Exceeds Expectations

Achaogen Inc (NASDAQ:AKAO) shares rose 14% today after the company reported positive top-line results from the phase 3 trial of its treatment for urinary …

Tuesday’s Volatile Stocks: Analysts Weigh in on Achaogen Inc (AKAO) and Proteon Therapeutics Inc (PRTO)

Achaogen Inc (NASDAQ:AKAO) investors are partying around after the company announced surprisingly positive results from both Phase 3 trials of plazomicin in CRE …

Needham’s Alan Carr Turns Bullish on Achaogen Inc (AKAO); Here’s Why

Achaogen Inc (NASDAQ:AKAO) shares were shooting through the roof at 148% yesterday after the biotech firm pleasantly surprised investors with two Phase 3 …